Pre-made Ecromeximab benchmark antibody (Whole mAb, anti-ganglioside GD3 therapeutic antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-INN-807

Anti-ganglioside GD3 therapeutic antibody (Pre-made Ecromeximab biosimilar, Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Ecromeximab is a chimeric monoclonal antibody being developed for the treatment of malignant melanoma.[1][2]

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-INN-807-1mg 1mg 3090
GMP-Bios-INN-807-10mg 10mg Inquiry
GMP-Bios-INN-807-100mg 100mg Inquiry
GMP-Bios-INN-807-xmg ≥100mg Inquiry
Shipping Cost: 760.00


Products Name (INN Index) Pre-Made Ecromeximab Biosimilar, Whole Mab: Anti-Ganglioside Gd3 therapeutic antibody
INN Name Ecromeximab
Targetganglioside GD3
FormatWhole mAb
Species Reactivityhuman
CH1 IsotypeIgG1 - kappa
VD LCIgG1 - kappa
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
CompaniesLudwig Institute for Cancer Research (New York NY USA) / Life Science Pharmaceuticals (LSP) (Darien CT USA)
Conditions Approved
Conditions Active
Conditions Discontinued
Development TechYB2/0 cell line: low fucosylation